In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.

The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.

The project is informing participants of familial hypercholesterolemia genetic test results, and hereditary breast and ovarian cancer, and Lynch syndrome results will follow.

With RNA sequence, expression quantitative trait locus, genome-wide association, and other data, researchers identified disease-related genes in the kidney glomerulus and tubule compartments.

California Institute of Technology's Frances Arnold was awarded half this year's Nobel Prize in Chemistry, while the University of Missouri's George Smith and the MRC Laboratory of Molecular Biology's Gregory Winter will split the other half.

The Wall Street Journal reports on the ethics of genetic testing for aesthetic traits in embryos.

Technology Review reports on startup Catalog Technologies' prototype to store data as DNA.

In Genome Biology this week: DNA methylation in soybean accessions, genetic ancestry of Uralic speakers, and more.

Oct
03
Sponsored by
Illumina

Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way.

In this webinar, Sandip Patel, MD will provide a review of biomarker research and discoveries in the field of Immunotherapy and Garret Hampton, PhD will discuss Illumina’s vision for Oncology and share how genomics will enable broader availability of comprehensive tumor sequencing to explore complex biomarkers and assess tumor mutational burden.

➢ Human induced pluripotent stem cell (iPSC) technology has provided unique ways to understand and
potentially treat human diseases using cells from individual patients.
➢ iPS cells are amenable to genomic modifications using site-specific gene editing technologies such as
CRISPR/Cas9, by which we can correct/ introduce precise disease causing mutations in patient or healthy
iPSCs, respectively.
➢ Genome edited iPSCs and their isogenic control (or parental line) offer highly-controlled experimental models
for reliable comparison of results.

The goal of this experiment was to utilize the Echo 525 Liquid Handler in assembling five, five-piece assemblies by substituting modular DNA pieces at the nanoliter scale. The Labcyte Echo Liquid Handler enables lower-cost methods and workflows to produce high-quality synthetic DNA constructs.